VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B - Business Wire

Submitted by Anonymous (not verified) on Tue, 04/12/2022 - 11:00

VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B  Business Wire